{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T01:51:00Z","timestamp":1773453060282,"version":"3.50.1"},"reference-count":31,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A., Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.1080\/13696998.2023.2196922","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T18:30:10Z","timestamp":1680114610000},"page":"574-580","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors"],"prefix":"10.1080","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2944-0240","authenticated-orcid":false,"given":"Miguel","family":"Escobar","sequence":"first","affiliation":[{"name":"Hematology, University of Texas Health Science Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1758-2786","authenticated-orcid":false,"given":"Neha","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Complete HEOR Solutions, North Wales, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8800-7746","authenticated-orcid":false,"given":"Sagnik","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Complete HEOR Solutions, North Wales, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1585-0414","authenticated-orcid":false,"given":"Swastik","family":"Bhattacharya","sequence":"additional","affiliation":[{"name":"Complete HEOR Solutions, North Wales, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5816-568X","authenticated-orcid":false,"given":"Jorge","family":"Caicedo","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Inc, Lexington, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9961-4576","authenticated-orcid":false,"given":"Michael","family":"Bullano","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Inc, Lexington, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7023-8378","authenticated-orcid":false,"given":"Bob G.","family":"Schultz","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Inc, Lexington, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"key":"e_1_3_9_2_1","volume-title":"Inst Clin Econ Rev","author":"Rind D","year":"2020","unstructured":"Rind D, Walton S, Agboola F, et\u00a0al. Valoctocogene roxaparvovec and emicizumab for hemophilia A: effectiveness and value; evidence report. Inst Clin Econ Rev. 2020."},{"key":"e_1_3_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.03.008"},{"key":"e_1_3_9_4_1","unstructured":"Data & Statistics | Hemophilia | NCBDDD |. Centers for Disease Control and Prevention September 2020. [cited March 2021]. Available from: https:\/\/www.cdc.gov\/ncbddd\/hemophilia\/data.html"},{"key":"e_1_3_9_5_1","doi-asserted-by":"publisher","DOI":"10.1586\/ehm.12.27"},{"key":"e_1_3_9_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000885"},{"key":"e_1_3_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_3_9_8_1","unstructured":"Hemophilia A. Genetic and Rare Diseases Information Center (GARD) \u2013 an NCATS Program. [cited 2021 March]. Available from: https:\/\/rarediseases.info.nih.gov\/diseases\/6591\/hemophilia-a#ref_5891"},{"key":"e_1_3_9_9_1","unstructured":"Treatment of Hemophilia. Centers for Disease control and Prevention. [cited 2021 March]. Available from: https:\/\/www.cdc.gov\/ncbddd\/hemophilia\/treatment.html"},{"issue":"6","key":"e_1_3_9_10_1","first-page":"479","article-title":"Factor VIII replacement is still the standard of care in haemophilia A","volume":"17","author":"Aledort L","year":"2019","unstructured":"Aledort L, Mannucci PM, Schramm W, et\u00a0al. Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfusion. 2019;17(6):479.","journal-title":"Blood Transfusion"},{"key":"e_1_3_9_11_1","unstructured":"Powell K Williams A Sheen J et\u00a0al. Uptake of Emicizumab-kxwh (Hemlibra) in the MO HealthNet population and impact on medical and pharmacy cost and utilization. Poster presented at: the AMCP eLearning Days 2020 April 20\u201324."},{"key":"e_1_3_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13877"},{"key":"e_1_3_9_13_1","unstructured":"Hemlibra (emicizumab). Roche. 2022. Available from: https:\/\/www.roche.com\/media\/releases\/med-cor-2017-11-16"},{"key":"e_1_3_9_14_1","unstructured":"IBM. IBM MarketScan research databases. [cited 2022 June 6]. Available from: https:\/\/www.ibm.com\/in-en\/products\/marketscan-research-databases\/databases"},{"key":"e_1_3_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2012.02909.x"},{"key":"e_1_3_9_16_1","first-page":"1","article-title":"Mean body weight, height, waist circumference, and body mass index among adults: United States, 1999\u20132000 through 2015\u20132016","volume":"122","author":"Fryar CD","year":"2018","unstructured":"Fryar CD, Kruszon-Moran D, Gu Q, et\u00a0al. Mean body weight, height, waist circumference, and body mass index among adults: United States, 1999\u20132000 through 2015\u20132016. Natl Health Stat Report. 2018;122:1\u201316.","journal-title":"Natl Health Stat Report"},{"key":"e_1_3_9_17_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.109.1.45"},{"key":"e_1_3_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13220"},{"key":"e_1_3_9_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4758.4758"},{"key":"e_1_3_9_20_1","doi-asserted-by":"publisher","DOI":"10.1037\/1082-989X.7.1.105"},{"key":"e_1_3_9_21_1","unstructured":"Shelby Livingston. Medicare Medicaid contain costs better than private insurers study says. 11 February 2019. [cited 2019 May 1]. Available from: https:\/\/www.modernhealthcare.com\/article\/20190211\/NEWS\/190219996\/medicare-medicaid-contain-costs-better-than-private-insurers-study-says."},{"key":"e_1_3_9_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10194303"},{"key":"e_1_3_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27886"},{"key":"e_1_3_9_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16964"},{"key":"e_1_3_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14318"},{"key":"e_1_3_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14261"},{"key":"e_1_3_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14212"},{"key":"e_1_3_9_28_1","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2021-0109"},{"key":"e_1_3_9_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146616"},{"key":"e_1_3_9_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122569"},{"key":"e_1_3_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14347"},{"key":"e_1_3_9_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2022.2102779"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2023.2196922","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T10:14:25Z","timestamp":1701944065000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2023.2196922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,17]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,31]]}},"alternative-id":["10.1080\/13696998.2023.2196922"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2023.2196922","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}